Krause W, Karras J, Jakobs U
J Chromatogr. 1983 Oct 14;277:191-9. doi: 10.1016/s0378-4347(00)84836-7.
An assay procedure for measuring plasma and urine levels of canrenone is described. The drug is extracted with n-hexane-toluene (1:1, v/v) after adding spirorenone as internal standard, and is then separated from plasma constituents and metabolites by high-performance liquid chromatography followed by UV detection at 285 nm. The limit of detection is less than 5 ng/ml. Interference with a series of spironolactone and canrenone metabolites was not observed. Plasma levels and renal excretion of canrenone after oral administration of 200 mg of spironolactone and intravenous injection of 200 mg of potassium canrenoate to a healthy male volunteer were measured.
本文描述了一种测定血浆和尿液中坎利酮水平的分析方法。加入螺内酯作为内标后，用正己烷 - 甲苯（1:1，v/v）提取药物，然后通过高效液相色谱法将其与血浆成分和代谢物分离，并在285nm处进行紫外检测。检测限小于5ng/ml。未观察到一系列螺内酯和坎利酮代谢物的干扰。对一名健康男性志愿者口服200mg螺内酯和静脉注射200mg坎利酸钾后，测定了坎利酮的血浆水平和肾脏排泄情况。
